Thomas Reardon led the development of Internet Explorer at Microsoft in 1994. He sold his neural-interface startup CTRL-labs to Meta in 2019 for between $500 million and $1 billion, then spent several years inside Meta Reality Labs running the team that turned CTRL-labs’s wrist-worn EMG technology into the company’s now-shipping Neural Band wristband. He left to co-found his next venture, Flourish, in 2024. The new company’s debut arrived this week. Flourish closed a $500 million round at a $2.5 billion valuation around 4 June 2026, with Jeff Bezos personally contributing close to $100 million after nearly doubling an initial $50 million commitment. Co-founder Rob Williams is a former Amazon S-team executive, which appears to be how the Bezos relationship anchored. The company is building Cortex AI, an architecture-layer system that uses connectomics, the cell-by-cell mapping of biological neural connections, to design AI models that target 20-50 watts of energy draw, roughly a laptop’s power consumption and an order of magnitude lower than a server-grade GPU. Flourish has no product yet.

The Reardon and CTRL-labs lineage

Reardon’s track record is what makes a $2.5 billion valuation with no product credible. He led the development of Internet Explorer at Microsoft in 1994, then left tech to pursue graduate neuroscience at Duke and Columbia University before co-founding CTRL-labs in 2015. CTRL-labs built a wrist-worn electromyography (EMG) device that read the electrical signals from muscle nerves and translated them into computer commands, the technical architecture that Meta subsequently scaled into the Neural Band wristband now shipping with the company’s mixed-reality hardware.

Meta acquired CTRL-labs in September 2019 for a price reported at the time as between $500 million and $1 billion. Reardon then ran neuromotor interface projects inside Meta Reality Labs until he left to co-found Flourish in 2024 with Rob Williams. Williams’s S-team background at Amazon is the most plausible direct line to the Bezos relationship: an S-team appointment at Amazon required Bezos’s direct sign-off during his tenure as CEO, which would have established the personal relationship that the Flourish round’s largest single check now tracks.

What Cortex AI actually does

Flourish’s stated thesis is that the AI industry is optimising at the wrong layer. The current race for AI efficiency is dominated by silicon-side bets: Groq builds specialised inference chips, Cerebras designs wafer-scale processors, Etched is building transformer-specific silicon. Each of these companies is trying to engineer a faster, lower-power chip that runs existing AI architectures. Flourish is betting that the underlying AI architectures themselves are the wasteful layer, and that reverse-engineering how biological brains process information at high efficiency will produce dramatically better algorithms that can run on existing hardware.

The technical bet is connectomics. The company is building an in-house neuroscience research division anchored on high-resolution electron microscopes to map individual neural connections in the brain at cell-level resolution, with particular focus on biological cortical columns (the basic functional units of mammalian cortex). The hypothesis is that the cortical column’s information processing architecture is the missing reference design that current artificial neural networks have failed to capture.

The Cortex AI energy target is 20-50 watts, in the range of a high-end laptop running multiple applications. A single server-grade Nvidia H100 GPU draws roughly 700 watts under full load. The AI industry’s current scaling trajectory needs an order-of-magnitude efficiency improvement just to remain within the available power-grid capacity. If Flourish delivers, the implication is that the same training compute could run on existing hardware at dramatically lower energy cost.

The Bezos brain pattern

The Flourish round is the third visible Jeff Bezos brain-research move in twelve months and the second in four days. Bezos Expeditions participates in Synchron (covered in Inside BCI’s 8 May piece on sovereign and tech-billionaire capital flowing into brain access). The Bezos Family Foundation committed $100 million to the Allen Institute’s Brain Health accelerator on 2 June 2026 (covered in Inside BCI’s 5 June piece). Bezos personally committed close to $100 million to Flourish in this 4 June round.

The three positions are structurally different but pattern-consistent. Bezos Expeditions in Synchron is an equity stake in a clinical-stage implantable BCI company. The Bezos Family Foundation Allen Institute commitment is philanthropic, funding fundamental neuroscience research on neurodegenerative disease. The Bezos personal Flourish position is a venture investment in a commercial neuro-AI architecture company. Three distinct legal vehicles (Expeditions / Family Foundation / personal), three distinct categories (clinical BCI / philanthropic research / commercial AI), with brain-research-and-neurotechnology as the common substrate.

For a Fortune 500 strategist tracking the BCI-and-neurotechnology category, the structural signal is that the Bezos brain-research footprint is now wider than any individual venture, philanthropy, or BCI implant company. It spans the full pipeline from clinical-stage implant work to fundamental disease-mechanism research to commercial AI architecture inspired by brain processing. The pattern emerged in three discrete steps over twelve months and accelerated to two steps in four days.

Where Flourish sits in the AI-and-BCI architecture

Flourish is not a BCI company. It does not build neural interfaces, does not implant electrodes, and does not target clinical patient populations. The company is building algorithms and AI architectures derived from connectomics, with the explicit goal of running on existing commodity hardware. The connection to the BCI category is the founder lineage (Reardon at CTRL-labs and Meta Reality Labs), the underlying neuroscience approach (connectomics, cortical column architecture, the same field of study underpinning the Allen Institute’s open-data brain atlases), and the same capital pool that backs clinical-stage BCI (Bezos, GV via Alphabet, Lux Capital’s broader deep-tech thesis).

The market-positioning frame for the piece is that the brain-research and BCI categories are now operating with overlapping capital structures, overlapping founder networks, and overlapping technical foundations across what previously read as three separate sectors: clinical BCI implants, fundamental neuroscience research, and AI-from-neuroscience. A reader who tracks any one of those three sectors should be tracking all three.

What to watch

The first signal is whether Flourish publishes any technical milestone before its expected Series B (typically 18-24 months from a $500 million Series A). The company is operating without a product, which is unusual at this valuation tier. Some indication that the connectomics-to-architecture translation produces measurable AI-efficiency gains in a controlled test environment would be the first credible technical disclosure.

The second signal is whether Reardon recruits visible neural-architecture engineering talent into Flourish. The company is operating with two founders and a $500 million capital base, but the staffing trajectory is the visible indicator of whether the architecture-layer thesis is being built out at the depth the valuation implies. CTRL-labs alumni in Meta Reality Labs would be the most natural recruiting pool, but Flourish has not publicly disclosed its team composition beyond Reardon and Williams.

The third signal is whether the Bezos brain-research footprint extends to a fourth move in 2026. Three positions across Synchron, Allen Institute, and Flourish in twelve months is a pattern. A fourth in the next quarter would establish it as the active category for the world’s wealthiest individual investor.

Sources

• AI startup Flourish reportedly raises $500M round backed by Jeff Bezos (SiliconANGLE, 4 June 2026)
• Internet Explorer creator Thomas Reardon raises $500M for Flourish, a brain-inspired AI efficiency startup valued at $2.5B (TheNextWeb)
• Bezos commits close to $100M to the startup reverse-engineering the human brain to solve AI’s power crisis (TechFundingNews, 5 June 2026, Sofia Chesnokova)
• Catalio’s Neuroscience Startup Flourish Emerges With Funding from Bezos, Google Ventures (citybiz)
• Flourish secures $500M from Jeff Bezos and top VCs for brain-inspired AI research (Crypto Briefing)
• Thomas Reardon profile (LinkedIn)